|
Market Closed -
Nasdaq
23:00:00 23/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 88.12 USD | -1.73% |
|
+0.46% | -7.44% |
| 10-22 | BioNTech, Gilead to test drug combination in advanced breast cancer trial | RE |
| 10-22 | BioNTech, Gilead to Test Combination Treatment for Breast Cancer | MT |
Company Valuation: BioNTech SE
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 54,749 | 34,159 | 22,698 | 26,387 | 19,497 | 19,766 | - | - |
| Change | - | -37.61% | -33.55% | 16.25% | -26.11% | 1.38% | - | - |
| Enterprise Value (EV) 1 | 53,358 | 20,496 | 11,253 | 16,879 | 12,356 | 8,670 | 10,014 | 10,498 |
| Change | - | -61.59% | -45.1% | 50% | -26.8% | -29.84% | 15.5% | 4.84% |
| P/E | 5.72x | 3.72x | 24.9x | -39.7x | -17.3x | -13.4x | -14.7x | -20.7x |
| PBR | 4.62x | 1.7x | 1.12x | - | 1.06x | 1.08x | 1.16x | 1.22x |
| PEG | - | -0.79x | -0.3x | 0x | -0.2x | -0.5x | 1.72x | 0.7x |
| Capitalization / Revenue | 2.89x | 1.97x | 5.94x | 9.59x | 6.79x | 11.1x | 11x | 8.69x |
| EV / Revenue | 2.81x | 1.18x | 2.95x | 6.14x | 4.31x | 4.88x | 5.57x | 4.62x |
| EV / EBITDA | 3.47x | 1.61x | 12.9x | -16.6x | -12.1x | -5.93x | -6.97x | -9.95x |
| EV / EBIT | 3.49x | 1.62x | 16.3x | -12.8x | -8.79x | -4.69x | -5.9x | -8.7x |
| EV / FCF | 72.5x | 1.55x | 2.41x | -69x | 44x | -5x | -5.47x | -6.81x |
| FCF Yield | 1.38% | 64.5% | 41.5% | -1.45% | 2.27% | -20% | -18.3% | -14.7% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 39.63 | 37.77 | 3.83 | -2.77 | -4.7 | -5.865 | -5.365 | -3.794 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 18,977 | 17,311 | 3,819 | 2,751 | 2,870 | 1,775 | 1,797 | 2,274 |
| EBITDA 1 | 15,359 | 12,766 | 873.8 | -1,016 | -1,022 | -1,462 | -1,437 | -1,055 |
| EBIT 1 | 15,284 | 12,643 | 690.4 | -1,314 | -1,405 | -1,848 | -1,696 | -1,207 |
| Net income 1 | 10,292 | 9,434 | 930.3 | -665.3 | -1,136 | -1,458 | -1,282 | -933.5 |
| Net Debt 1 | -1,391 | -13,663 | -11,445 | -9,508 | -7,141 | -11,097 | -9,753 | -9,268 |
| Reference price 2 | 226.68 | 140.56 | 95.48 | 110.06 | 81.08 | 78.69 | 78.69 | 78.69 |
| Nbr of stocks (in thousands) | 241,521 | 243,019 | 237,716 | 239,740 | 240,455 | 251,204 | - | - |
| Announcement Date | 3/30/22 A | 3/27/23 A | 3/20/24 A | 3/10/25 A | 3/10/26 A | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -13.42x | 4.88x | -5.93x | -.--% | 22.13B | |
| 18.83x | 6.63x | 13.18x | 1.58% | 64.69B | |
| 30.16x | 7.93x | 26.43x | 0.05% | 54.78B | |
| 36.79x | 6.53x | 19.51x | 0.88% | 53.49B | |
| 35.59x | 3.45x | 14.87x | -.--% | 45.98B | |
| 49.71x | 5.74x | 31.52x | -.--% | 42.94B | |
| -19.41x | 187.75x | -20.66x | -.--% | 40.08B | |
| 28.93x | 8.21x | 21.27x | 0.37% | 33.52B | |
| 32.66x | 5.97x | 20.09x | -.--% | 23.67B | |
| 27.67x | 5.83x | 15.12x | -.--% | 23.97B | |
| Average | 22.75x | 24.29x | 13.54x | 0.29% | 40.52B | |
| Weighted average by Cap. | 24.53x | 24.20x | 14.74x | 0.41% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- BNTX Stock
- Valuation BioNTech SE
Select your edition
All financial news and data tailored to specific country editions
